UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~January~~March 2025

Commission File Number: 001-42450

Zhengye Biotechnology Holding Limited

No.1 Lianmeng Road, Jilin Economic & Technical Development Zone ~~Jilin City, Jilin Province, China~~

Jilin City, Jilin Province, China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~On January~~Appointment ~~13, 2025, Kingswood Capital Partners, LLC (“Kingswood”), as the representative~~ of the underwriters of the initial public offering of Zhengye Biotechnology Holding Limited (the “Company”), exercised its over-allotment option in full to purchase an additional 225,000 ordinary shares of the Company at the public offering price of US$4Mr.00 ~~per~~Aiden ~~share~~Han ~~(the~~as ~~“Option”). The closing for the sale of the over~~Co-~~allotment~~Chief ~~shares~~Executive took place on January 14, 2025. As a result, the gross proceeds of the Company’s initial public offering, including the proceeds from the sale of the over-allotment shares, totaled US$6,900,000, before deducting underwriting discounts and other related expenses.Officer

~~A copy~~On ofMarch ~~the~~5, ~~press~~2025, ~~release announcing~~ the ~~underwriters’~~nominating ~~exercise of the Option is attached as Exhibit 99.1~~ and ~~incorporated herein~~corporate bygovernance ~~reference.~~committee ~~This~~(the ~~report~~“Nominating ~~does~~Committee”) ~~not~~of ~~constitute~~the anboard ~~offer~~of todirectors ~~sell, or~~ (the ~~solicitation~~“Board”) of anZhengye ~~offer to buy, nor shall there be any sale of~~Biotechnology ~~these~~Holding ~~securities~~Limited in(the ~~any~~“Company”) ~~state~~recommended, orand ~~jurisdiction~~the inBoard ~~which such offer~~appointed, ~~solicitation,~~Mr. orAiden ~~sale~~Han ~~would~~to beserve ~~unlawful~~as ~~prior to~~ the ~~registration or~~Co-Chief ~~qualification~~Executive ~~under~~ Officer (the ~~securities~~“Co-CEO”) ~~laws~~ of ~~any~~the ~~such~~Company, ~~state~~effective orMarch ~~jurisdiction~~5, 2025.

~~EXHIBIT~~Aiden Han, age 32, is the son of Zhenfa Han, a ~~INDEX~~director and the chairman of the Board of the Company. He received his bachelor’s degree in business administration from University of Southern California in 2017.

Exhibit No.		Description
99.1		Press Release dated January 14, 2025, announcing the exercise of the over-allotment option.

To the best knowledge of the Company, there is no understanding or arrangement between Aiden Han and any other person pursuant to which he was appointed as the Co-CEO.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Zhengye Biotechnology Holding Limited
Date: January 14, 2025	By:	/s/ Songlin Song
Date: March 6, 2025	By:	/s/ Songlin Song
	Name:	Songlin Song
	Title:	Chief Executive Officer

Filing Compare · Zhengye Biotechnology Holding Ltd